Redmile Group

Redmile Group pursues a crossover strategy focused exclusively on healthcare. The firm invests across private and public markets, targeting biotechnology, medical devices, diagnostics, and healthcare services companies. This approach allows the firm to support innovation from early-stage venture through later-stage growth and into public equities, applying a consistent research-driven underwriting process throughout.

No. Redmile invests in both private and public healthcare companies. The firm's mandate includes venture capital, growth equity, and public market investments such as PIPE transactions and pre-IPO crosses. This crossover capability is a core structural feature of the firm.

Redmile Group explicitly focuses on healthcare and does not invest outside this sector. The firm avoids generalist allocations to areas like enterprise software, consumer technology, financial services, or energy. Its entire analytical and operational structure is built around healthcare specialization.

Redmile sources opportunities through a combination of direct scientific networks, relationships with academic and clinical institutions, and its cross-market presence. The firm's ability to invest across private and public markets gives it visibility into company lifecycles and management teams that can span both venture and public equity stages.

Redmile is not structured as a traditional venture capital firm. It operates as a crossover healthcare investment manager with the ability to deploy capital in both private and public markets. This contrasts with venture firms that typically exit at IPO, as Redmile can continue to hold and invest in companies as they transition to public market securities.